Recapitulation of the evolution of biosynthetic gene clusters reveals hidden chemical diversity on bacterial genomes

Pablo Cruz-Morales¹,*, Christian E. Martínez-Guerrero¹, Marco A. Morales-Escalante¹, Luis Yáñez-Guerra¹, Johannes Florian Kopp², Jörg Feldmann², Hilda E. Ramos-Aboites¹ & Francisco Barona-Gómez¹,*

¹ Evolution of Metabolic Diversity Laboratory, Langebio, Cinvestav-IPN. Irapuato, Guanajuato, México.

² Trace Element Speciation Laboratory (TESLA), College of Physical Sciences. Aberdeen, Scotland, UK.

Authors for correspondence:

Francisco Barona-Gómez (fbarona@langebio.cinvestav.mx)
Pablo Cruz-Morales (pcruz@langebio.cinvestav.mx)
Abstract

Natural products, which result from secondary or specialized metabolism, have provided molecules to human welfare for millennia. However, decline of chemical discovery pace has imposed a pressure upon human health, such as in antibiotic resistance. Current genome mining approaches have revitalized research into natural products, but the empirical nature of these methods limits the chemical space that is explored. By means of integrating evolutionary concepts related to emergence of specialized metabolism, we have gained fundamental insights that are translated into the discovery of hidden chemical diversity through a unique and unbiased genome mining approach. This method, termed EvoMining, can be defined as a functional phylogenomics platform for identification of expanded, repurposed enzyme families, with the potential to catalyze new conversions. A bioinformatics pipeline is proposed and validated by comparing its performance with the state-of-the-art genome mining approach antiSMASH. Moreover, as the founding assumption of EvoMining relates to the evolution of enzyme function, our approach was experimentally validated after solving two milestone problems that include unprecedented enzyme conversions. First, we report the discovery of a biosynthetic gene cluster for an orphan metabolite, which could not be unveiled with current methods, i.e. the biosynthesis of the protease inhibitor leupeptin by *Streptomyces roseus* ATCC 31245. Second, we characterized a novel enzyme, catalyzing the formation of an arsenic-carbon bond, in model organisms that have been thoroughly mined, i.e. *Streptomyces coelicolor* and *Streptomyces lividans*. This work provides evidence that bacterial chemical repertoire is still underexploited, as well as an alternative approach that promises to speed up the discovery of novel enzymes and biosynthetic logics that can feedback into current genome mining methods.
Introduction

The concept of genome mining can be defined as both an extension of the central dogma of molecular biology, situating metabolites at the downstream end, and a novel approach that promises to turn the discovery of natural products (NPs) drugs into a chance-free endeavor (1–3). Within the context of increased antibiotic resistance and emergence of modern diseases, and given the strong track of NPs (which are the result of secondary or specialized metabolism) in providing useful molecules to human welfare (3, 4), genome mining has revitalized the investigation into NP biosynthesis and their mechanisms of action (3, 5). Evidence for this has steadily increased since the first NP that was discovered using genome mining approaches, i.e the farnesylated benzodiazepinone ECO4601, entered into human clinical trials more than a decade ago (6–8).

In contrast to experimental hurdles, which have been acknowledged elsewhere (9), in silico genome mining has enjoyed a relatively higher success. Early genome mining approaches built up from the merger between a wealth of genome sequences and an accumulated biosynthetic empirical knowledge, mainly surrounding polyketide synthases (PKS) and Non-Ribosomal Peptide Synthetases (NRPSs) (10, 11). These approaches, which rely on high quality genome sequences due to the modularity and repetitive nature of PKSs and NRPSs, can be classified as: (i) chemically-driven, where the structure of a metabolite is linked to potential enzymes, such that the biosynthetic genes of an ‘orphan’ metabolite that has been isolated and structurally characterized, are identified (12) ; or (ii) genetically-driven, where known sequences of protein domains (13) or active-site motifs (14) help to identify putative biosynthetic gene clusters (BGCs) and their products. The latter relates to the term ‘cryptic’ BGC, defined as a genetic locus that has been predicted to direct the synthesis of a NP, but which remains to be experimentally confirmed (15).
Genome mining of NPs has also helped to prioritize strains and metabolites on which to focus for further investigation. During this process, based on \textit{a priori} biosynthetic insights, educated guesses surrounding PKS and NRPS can be put forward, increasing the likelihood of discovering interesting chemical and mechanistic variations. Moreover, biosynthetic logics for a growing number of NP classes, such as phosphonates (16–18) and ribosomally synthesized post-translationally modified peptides (RiPPs) (19) are further complementing early NRPS/PKS-centric approaches. Nevertheless, the current pace of deciphering novel biosynthetic logics, which can only be achieved after long periods of research, hampers our ability to cope with the rate of appearance of antibiotic resistance. Moreover, focusing in known chemical scaffolds with the concomitant high rate of rediscovering the same classes of NPs, although useful under certain circumstances and specific cases (20), seems sub-optimal for the discovery of much-needed novel drugs. From these observations it becomes apparent that more efficient approaches that will lead to the discovery of novel chemistry are needed.

In this work we have developed an alternative method for current NP genome mining, which is guided by evolutionary theory. By means of integrating three evolutionary concepts related to emergence of specialized metabolism, we have gained fundamental insights that are translated into the discovery of novel NPs. First, we embraced the concept that new enzymatic functions evolve by retaining their reaction mechanisms, while expanding their substrate specificities (21). In consequence, this process expands enzyme families. Second, evolution of contemporary metabolic pathways frequently occurs through recruitment of existing enzyme families to perform new metabolic functions (22). Indeed, in the context of NP biosynthesis, cases of functional overlap driven by promiscuous enzymes that have been expanded and recruited have been reported (23, 24). The correspondence of enzymes to either central or specialized metabolism
is typically solved through detailed experimental analyses, but we argue here that these could also be achieved through phylogenomics. Third, BGCs are rapidly evolving metabolic systems, consisting of smaller biochemical sub-systems or ‘sub-clusters’, which may have their origin in central metabolism (25–27).

Integration of these three evolutionary principles was formalized as a bioinformatics pipeline, termed EvoMining, which can be defined as a functional phylogenomics tool for identification of expanded, repurposed enzyme families, with the potential to catalyze new conversions in specialized metabolism. As this process does not rely on sequence similarity searches of previously identified NP biosynthetic enzymes, but rather on recapitulation of an evolutionary process, the predictive power of evolutionary theory is fully embraced. Moreover, given that predictions are done at the single-gene level, rather than looking at large PKS, NRPS or BGC sequence assemblies, low quality draft genome sequences are compatible with this approach. Indeed, we demonstrate that EvoMining can predict biosynthetic genes for orphan molecules, as well as new NP biosynthetic pathways in model strains, both involving novel enzymatic conversions.

Experimentally, we focused in the phylum Actinobacteria, which includes renowned NP-producing genera that have provided a plethora of useful NPs to human welfare, such as Streptomyces (3). Experimental evidence for two critical cases using Streptomyces species, needed to advance the field of genome mining of NPs, is reported. First, the BGC for the biosynthesis of the orphan small peptide aldehyde (SPA) leupeptin, of high economic importance, is identified in the genome of Streptomyces roseus ATCC 31245. Second, a novel NP synthesized by the model organisms Streptomyces coelicolor A3(2) and Streptomyces lividans 66 is experimentally characterized. Both of these case studies include novel chemical conversions catalyzed by
enzymes that were blindly targeted by EvoMining. Therefore, these results validate EvoMining as an alternative and complementary method for the discovery of potential drug leads. Moreover, the insights gained during this integrative approach suggest that bacterial genomes encode a larger chemical diversity yet-to-be discovered that can be untapped by means of using evolutionary theory.

Results & Discussion

The EvoMining bioinformatics pipeline, in its current version 1.0, uses three input databases (green cylinders, Figure 1A). First, a genome database that contains the annotated genomes of 230 members of the phylum *Actinobacteria*, as retrieved from the GenBank database (Table S1). Second, a database containing the amino acid sequences of enzymes belonging to nine ‘precursor supply central metabolic pathways’ (PSCP), defined as previously (28). This dataset provides a universe of 103 enzyme families, to be used as query sequences (Table S2), which were extracted from genome-scale metabolic network reconstructions (GSMR) of model *Actinobacteria*. Third, a NP seed database consisting of 226 experimentally characterized BGCs (mainly from *Actinobacteria*), including: (i) NRPSs and PKSs biosynthetic systems extracted from specialized databases (10, 11); and (ii) other classes of well-described NPs biosynthetic pathways, e.g. terpenes, phosphonates and RiPPs, extracted from the literature (Table S3).

The sequences in the PSCP database were used as queries to retrieve homologous sequences contained in the genome database. The threshold used for defining homology was non-conservative, such that expansion events resulting from both gene duplication and horizontal gene transfer could be retrieved. When propagated through the genomes database, after homology
searches, these query sequences gave rise to an enzyme family internal database. After a heuristic approach, an organism’s enzyme expansion was called by statistical measure when the number of homologs on its genome was larger than the average of each enzyme family plus its standard deviation. The enzymes that complied with this criterion were stored on the enzyme expansion internal database (yellow cylinders, Figure 1A; Table S4). The expansion of each enzyme family was sorted throughout a phylogenetic species tree (Tree S1), allowing taxonomic resolution of expansions, as previously observed (28). With this approach we found that 98 enzyme families, out of 103 enzymes from the PSCP database, had expansion events.

A critical function for the EvoMining approach is identification of enzyme families expanded in concert with NP biosynthesis clusters. To accomplish this, the expanded enzyme families were then mined for recruitment of their members within the context of NP biosynthesis. In the cases where an expanded enzyme family could be connected via sequence homology to one or more proteins within the NP seed database, their sequences were stored on the enzyme recruitment internal database (yellow cylinders, Figure 1A, Table S5). It should be noted that only a fraction of all sequences in the NP seed database have been characterized in the context of NP biosynthesis. Therefore, the functional association between recruited enzymes and this relatively large sequence space is supported by the occurrence of the expanded enzymes within BGCs that have been linked to a known metabolite. The enzyme recruitment internal database consisted of 23 enzyme families, including both known recruitments, e.g. aconitase in phosphinothricin biosynthesis (16), and all related sequences codified by the analyzed genomes. Thus, the functional potential of the NP seed and the genome databases, together, is fully exploited.
The sequences of the recruited enzymes, together with those from the expanded enzyme families, were used to make multiple sequence alignments (MSA) and Bayesian phylogenetic reconstructions (Figure 1A). Moreover, in order to provide useful functional annotation for interpretation of EvoMining phylogenetic trees (Figure 1B), a bidirectional best-hit analysis, between the enzyme recruitment and the PSCP databases, was used for directing the labeling of central metabolic orthologs (red branches). We adopted this simple strategy, as it is safe to assume that NP biosynthetic enzymes will highly diverge from central metabolic homologs. Homologs related to the very few known recruitments (blue branches) were therefore considered to be NP biosynthetic homologs identified by EvoMining. This proof-of-concept analysis provided 515 recruitment events, which were called EvoMining hits, and their gene identifiers (GIs) were used as queries to retrieve contigs (12-109 kbp, 71.3 Kbp in average, 19.9 Kbp standard deviation). The retrieved contigs were then analyzed for putative NP BGCs using antiSMASH and ClusterFinder (29, 30). When an NP positive hit was obtained after this process, this was also noted in the phylogenetic tree (cyan branches).

The abovementioned functional annotation provides information that validates NP-related phylogenetic clades that consist of EvoMining hits (Figure 1B). Subtraction of the known (blue branches) and antiSMASH / ClusterFinder predicted (cyan branches) NP lineages, within the NP-related clades, reveals putative BGCs coding for repurposed enzymes only accessible by EvoMining (green branches). Henceforth, we refer to these homologs as EvoMining predictions, which we define as unknown NP biosynthetic enzymes supported by phylogenetic evidence encoded within previously undetected BGCs. Chemically, an implication of an EvoMining hit is that it uncovers enzymatic conversions, mainly involving diverging substrate specificities (but potentially also mechanistic variations), which in turn can lead to alternative biosynthetic logics.
and therefore chemical scaffolds. Thus, an EvoMining prediction, as a concept, is here applied to entire BGCs rather than to specific enzymes. In addition to Figure 1, EvoMining version 1.0 can be explored at http://148.247.230.39/newevomining/new/evomining_web/index.html.

Evolutionary insights and performance of EvoMining

Of the 515 EvoMining hits we successfully retrieved contigs containing their cognate enzyme coding genes for 448 of them (71.3 kbp on average; 87 %) (Table S5). Among these, many EvoMining hits (20 %) were included in contigs with internal gaps, which hampers sequence annotation. This subset, together with the remaining 13 % of the total hits whose contigs could not be retrieved, account for one third of contigs that come from highly fragmented genomes. So, the advantage of EvoMining in this respect is that predictions can be made, early on during analysis, in draft genomes that can be further improved. This provides an opportunity to prioritize in cost-effective manner large strain collections during genome-driven drug discovery efforts. Focusing on an EvoMining hit related to the enolase enzyme family (Tree S2), which was found in the genome of Streptomyces sviceus (1 scaffold of 9 Mbp with 552 gaps and 8X coverage, GI: 297196766), illustrates the benefit of EvoMining in this respect. The contig containing this recruited enolase (GI: 297146550) had 6 gaps including missing sequence at its 5’ end. After closing of these gaps by sequencing PCR products, the complete sequences for several phosphonate-related enzymes, namely, alcohol dehydrogenase (phpC), phosphonopyruvate decarboxylase (ppd), nicotinamide mononucleotide adenyl transferase (phpF), carboxy-phosphonoenolpyruvate synthase (phpH, EvoMining hit) and aldehyde dehydrogenase (phpJ), could be annotated. Further sequence analysis suggested that indeed this locus encodes for a putative phosphonate BGC related to phosphinothricin (31) (Text S1, Figures S1 and S2).
We further asked the question of whether EvoMining enzymes are indeed encoded within BGCs potentially directing the synthesis of NPs. The retrieved contigs were mined for BGCs of known classes of NPs using antiSMASH (29) as well as for putative new BGCs using ClusterFinder (30). From this analysis we found that these tools could predict BGCs for 62.5 % and 10.5 %, respectively, of the contigs harboring EvoMining hits (73 % together). The remaining 27 % of contigs are unique EvoMining hits, and therefore potentially EvoMining predictions related to emerging BGCs and chemical scaffolds (Figure 2A). The enzymes included in this 27 % represent the core of EvoMining, and due to the lack of functional information subsequent analysis is experimentally and bioinformatically challenging. However, manual analysis of the green branches within the NP-related clade provided as an example in Figure 1B, allowed us to identify a highly conserved BGC-like loci present in the genus *Streptomyces* (see below discussion related to Figure S7, Table S7 and S8).

As a first step towards eventual characterization of completely unprecedented BGCs we determined whether EvoMining hits are associated to particular BGC classes. For this purpose, we used antiSMASH to classify and count for the number of BGCs contained in each contig. Globally, BGCs for 22 out of the 24 categories used by antiSMASH (29) could be detected. Only aminoglycosides and indoles could not be detected, which may be due to the limited enzymatic repertoire explored by our seed NP and PSCP input databases. Among the 22 antiSMASH categories, type I PKSs and NRPSs represent the most abundant classes (Figure S3), confirming that EvoMining can identify well-known NP biosynthetic systems following a unique, non-biased strategy. Despite this convergence, at least with this limited analysis, it was also found that the number of EvoMining hits increased in parallel to the number of BGC classes (Figure 2B).
implication of this observation is that novel classes may be discovered for any given enzyme recruitment, as long as enough sequence space is explored.

For instance, among the 23 recruited enzyme families, only that of indole-3-glycerolphosphate synthase was linked to a single class of BGCs. It should be noted, however, that this family has the smallest number of EvoMining hits. At the other end, the enzyme families with the larger number of EvoMining hits showed the highest BGC diversity, namely, 17 BGC classes for the asparagine synthetase enzyme family, followed by 10 BGC classes for both 3-phosphoshikimate-1-carboxyvinyl-transferase and 2-dehydro-3-deoxyphosphoheptonate aldolase families (Figure 2B). It seems, therefore, that some of the recruitments have high predictive potential when used as beacons for detection of BGCs. The latter may be due to the evolvability of enzymes towards specificities for common precursors of NPs, driven by enzyme promiscuity (23, 24), or because these enzymes catalyse recurrent reactions in NP biosynthesis with less mechanistic restrictions (27).

After our in silico analysis, we aimed to demonstrate that EvoMining could indeed be used to predict enzymes of unknown function involved in the synthesis of NPs. More specifically, we focused in providing experimental evidence to support two critical cases, which could not be solved with current methods: (i) the discovery of a BGC of an orphan metabolite that has been extensively investigated; and (ii) the discovery of a BGC driving the synthesis of an NP produced by well-studied model strains. Remarkably, and in agreement with the definition of an EvoMining hit, the enzymes identified by this approach are proposed to catalyse unprecedented chemical conversions. These enzymes may have occurred through convergent evolution, or after high sequence divergence, hampering the possibility of detecting them after sequence similarities searches.
**Discovery of leupeptin BGC in *Streptomyces roseus*: the orphan metabolite problem**

Leupeptin is the first member of a large family of NPs generically known as small peptide aldehydes (SPA), and it is widely used in industry and bioresearch due to its potent anti-proteolytic activity (32). Despite the fact that leupeptin was discovered during the golden age of antibiotic research (32) its BGC remained elusive until now (Figure 3). The structure of leupeptin includes a C-terminal aldehyde group in a peptide chain that includes an acyl group at its N-terminal end. Early biochemical studies of leupeptin revealed that: (i) this peptide is produced from acetate, leucine and arginine; (ii) an ATP-dependent synthetase is responsible for the condensation of an acetyl-leucine-leucine intermediary; (iii) this intermediary is released from an enzymatic complex before its condensation with an arginine residue; and (iv) the enzymatic complex responsible for the synthesis of acetyl-leucine-leucine-arginine, called leupeptidic acid, has a molecular mass of approximately 320 KDa (33–36).

A more recent study on the biosynthesis of the SPA flavopeptin produced by *Streptomyces* sp. NRRL-F6652 (37), suggested that synthesis of leupeptin by producing strains, such as *S. roseus* ATCC 31245 (32), may occur via a distinctive NRPS complex. Key features of this putative NRPS were proposed to be: (i) an acyl transfer domain typically found as an N-terminal starter C-domain, responsible for initial acylation of non-ribosomal peptides (38); (ii) three complete modules for peptide synthesis, two for leucine and one for arginine residues; and (iii) a reductase domain at its C-terminal end, responsible for reductive peptide release, leading to an aldehyde. Based in this modern proposal, after sequencing the genome of *S. roseus* ATCC 31245 (genome accession number pending), we searched for flavopeptin-like NRPSs. However, this approach proved to be unsuccessful.
Mining of the *S. roseus* genome sequence with EvoMining, by contrast, produced a hit to an enzyme annotated as argininosuccinate lyase (ASL), typically involved in arginine biosynthesis. ASLs condense succinate and arginine via an amidic bond at the guanidine group of the arginine in a reversible reaction (39). Indeed, two ASL homologs sharing 25% amino acid sequence identity, which could be phylogenetically resolved, were found in the genome of *S. roseus* (Figure 3A and Tree S3). The first homolog, as expected, is located within a clade that includes central metabolic homologs (ASL1 or *argH* gene); whereas the second homolog is located in a clade together with enzymes previously related to the biosynthesis of uridyl-peptides, namely, napsamycin and pacidamycin (40, 41). Thus, the members of the latter clade, termed here ASL2, are predicted to include recruited enzymes involved in NP biosynthesis, and that these enzymes are performing a related but different chemistry than that catalyzed by ASL1.

After detailed annotation of the region surrounding the recruited ASL2 gene, a NRPS, was found (Figure 3A). The product of this gene was predicted to have an N-terminal condensation domain (C1), followed by an adenylation domain predicted to bind threonine (A1); a peptidyl carrier protein domain (PCP1); a second condensation domain (C2); an adenylation domain predicted to bind serine (A2); a second peptidyl carrier protein (PCP2); and a thioesterase domain (TE) (Figure 3B). On the basis of this annotation, which drastically differs to the prediction based in the flavopeptin system, we predicted that this NRPS would produce an acylated dipeptide, which is released upon the action of the thioesterase domain. This biosynthetic logic is indeed consistent with the early biochemical data available for leupeptin (33–36).

We therefore renamed the EvoMining hit as *leupB*, and the NRPS as *leupA*, and a functional association between LeupA and LeupB was assumed. Specifically, we speculated that LeupB is capable of condensing the dipeptide produced by LeupA, possibly acyl-Leu-Leu, with an arginine residue, leading to leupeptidic acid or acyl-Leu-Leu-Arg peptide (Figure 3C). In
accordance with this hypothesis the total predicted mass of LeupA and LeupB is 318 KDa, which is strikingly close to that mass of 320 KDa early on estimated by Umezawa and co-workers for the complex directing leupeptidic acid formation (36). Additional genes downstream of leupB, transcribed in the same direction and therefore possibly involved in leupeptin biosynthesis include leupC and leupD, that are annotated as a threonine kinase and cysteine synthase, respectively (Figure 3B). The relevance of this functional annotation remains to be further investigated, but may have to do with reduction of the leupeptidic acid or other non-apparent functions.

To demonstrate that the predicted locus is involved in leupeptin biosynthesis, we used insertional mutagenesis to disrupt the leupA gene. We chose this rather simple approach due to the lack of genetic tools for manipulation of S. roseus, and because this gene could be considered to be essential for synthesis of leupeptin. We did not target leupB, as the central ASL homolog may complement its function via enzyme promiscuity, masking the expected phenotype (unless a double mutant is obtained) as previously reported in other BGCs (23). The S. roseus leupA mutant, termed PCMSr1, was obtained, and after comparative LC-MS analysis of this mutant with the parental wild-type strain, it was found that mutation of leupA renders PCMSr1 unable to produce leupeptin. The peak absent from the LC chromatograms obtained from PCMSr1, present in the wild type strain, corresponds with leupeptin authentic standard, as confirmed after electrospray ionization (ESI) mass spectrometry (m/z 427) and fragmentation pattern (ms² of 367 and 409) (Figures S4A and S5).

To further establish a link between leupeptin biosynthesis and the postulated locus, currently involving leupA-D (Figure 3), we constructed a genomic library from which two clones, containing at least these four genes, were isolated. Both constructs were introduced into E. coli DH10B, and the resulting transformants were used for comparative fermentation experiments. LC-MS analysis of these cultures revealed that extracts of supernatants from both strains presented
fractions with peaks with same retention times and expected mass as authentic leupeptin standard (Figures S4B and S5). Therefore, we concluded that this locus, as predicted using EvoMining, is indeed directing the synthesis of leupeptin in *S. roseus* ATCC31245. However, given that the constructs bearing the *leupABCD* genes are 65 to 70 Kbp in size (clone 8_10B and 9_18N, respectively), the involvement of further genes in leupeptin biosynthesis, which are included in these constructs, cannot be ruled out at current time.

**Discovery of an arseno-organic enzyme in *Streptomyces lividans* and *Streptomyces coelicolor*: novel chemistry in model organisms.**

For the second case, we aimed to identify a novel NP in the model organisms *S. coelicolor* A3(2) and *S. lividans* 66, that have been mined thoroughly, and presumably most of their NP repertoire has been elucidated (42). Furthermore, several methods for genetic manipulation of these two strains are available (43), making these organisms ideal for these proof-of-concept experiments. EvoMining hits for these two strains include recruitments belonging to the 3-phosphoshikimate-1-carboxyvinyltransferase enzyme family. This enzyme, or AroA, catalyzes the transfer of a vinyl group from phosphoenolpyruvate (PEP) to 3-phosphoshikimate forming 5-enolpyruvylshikimate-3-phosphate and releasing phosphate. The reaction is part of the shikimate pathway, a common pathway for the biosynthesis of aromatic amino acids and other metabolites (44).

The phylogenetic reconstruction of the actinobacterial AroA enzyme family (Fig 1B and Tree S4), as expected, shows a major clade associated with central metabolism; this clade includes SLI_5501 from *S. lividans* and SCO5212 from *S. coelicolor*. The phylogeny also has a divergent clade that includes two family members linked to the BGCs of the polyketide
asukamycin (45) and phenazines (46), as well as AroA homologs from 26 % of the genomes in the database. In *S. coelicolor* and *S. lividans* these recruited homologs are encoded by SLI_1096 and SCO6819, respectively. Moreover, in *S. lividans*, these orthologous genes are located within a large genome island, SliGI-1, which has been functionally linked to metal homeostasis (47), and they are situated only six genes upstream of a two-gene PKS system spanning SCO6826-7 and SLI_1088-9, respectively. This PKS was identified in *S. coelicolor* since the early days of the genome mining of this organism, but often it was referred to as a cryptic BGC (48, 49). Indeed, the divergent AroA homologs have not been associated with it. Furthermore, these homologs are classified as “other genes” when both genomes are mined using antiSMASH.

The gene neighborhood of these *aroA* genes is highly conserved between the genomes of *S. lividans* and *S. coelicolor*. Thus, from this point onwards we will refer to the *S. lividans* genes only. The syntenic region spans from SLI_1077 till SLI_1103, including several biosynthetic enzymes, regulators, transporters and the PKS, suggesting that these genes, together with other biosynthetic genes in this locus, are functionally linked and form a single BGC (Figure 4A). Detailed annotation of this BGC (Table S5) revealed the presence of a 2,3-bisphosphoglycerate-independent phosphoenolpyruvate mutase enzyme (SLI_1097; PPM), downstream and possibly transcriptionally coupled to the *aroA* homolog. Thus, a functional link between these genes, as well as with phosphonopyruvate decarboxylase gene (PPD; SLI_1091) encoded in this BGC, was proposed. The combination of mutase-decarboxylase enzymes is a conserved biosynthetic feature of NPs containing carbon-phosphate bonds (16).

Other non-enzymatic functions were found encoded within this BGC, including a set of ABC transporters, originally annotated as phosphonate transporters (SLI_1100 and SLI_1101). Four arsenic tolerance-related genes (SLI_1077-1080) located upstream of the PKS could also be
annotated. These genes are paralogous to the main arsenic tolerance system encoded by the *ars* operon (50), which is located at the core of the *S. lividans* chromosome (SLI_3946-50). This BGC also codes for regulatory proteins, mainly arsenic responsive repressor proteins (SLI_1078, SLI_1092, SLI_1102 and SLI_1103). Thus, overall, our detailed annotation suggests a link between arsenic and phosphonate biosynthetic chemistry. Accordingly, in order to reconcile the presence of phosphonate-like biosynthetic, transporter and arsenic resistance genes, within a BGC, we postulated a biosynthetic logic analogous to that of phosphonate biosynthesis, but involving arsenate as the driving chemical moiety (Figure 4A).

The abovementioned hypothesis was further supported by the three following observations. First, arsenate and phosphate are similar in their chemical and thermodynamic properties, causing phosphate and arsenate utilizing enzymes to have overlapping affinities and kinetic parameters, although arsenate-derived products are more labile. Indeed, as exemplified in the two next points, arsenic compounds are commonly used as analogs of native substrates in mechanistic studies of phosphate enzymes (51, 52). Second, previous studies have demonstrated that AroA is able to inefficiently catalyze a reaction in the opposite direction to the biosynthesis of aromatic amino acids, namely, the formation of PEP and 3-phosphoshikimate from enolpyruvyl shikimate 3-phosphate and phosphate (44). However, since phosphate is an intrinsically non-reactive substrate, the demonstration of the backwards reaction catalyzed by AroA requires the use of phosphate analogues. Indeed, arsenate and enolpyruvyl shikimate 3-phosphate can react to produce arsenoenolpyruvate (AEP), a labile analog of PEP, which is spontaneously broken down into pyruvate and arsenate (44). Third, it has been demonstrated that the phosphoenolpyruvate mutase, PPM, an enzyme responsible for the isomerization of PEP to produce phosphonopyruvate, is capable of recognizing AEP as a substrate. Although at low catalytic efficiency, the formation of
3-arsonopyruvate by this enzyme, a product analog of the phosphonopyruvate intermediate in phosphonate NPs biosynthesis (16), has been previously demonstrated (53).

The previous evidence was used to postulate a novel biosynthetic pathway encoded by SLI1077-SLI1103. A putative arseno-organic product synthesized by this pathway may resemble the structural characteristics and properties of a phospolipid. A detailed functional annotation, and biosynthetic proposal, is provided as supplementary information (Figure S6 and Table S6). To determine the product of the predicted BGC we used expression analysis, as well as comparative metabolic profiling of wild type and mutant strains, in both S. lividans and S. coelicolor. Using RT-PCR analysis, we first determined the transcriptional expression profiles of the PKS (SLI1088), aroA (SLI1096), one of the arsR-like regulator (SLI1103), and the periplasmic-binding protein of the ABC-type transporter (SLI1099). As expected for a cryptic BGC, the results of these experiments demonstrate that the proposed pathway is repressed under standard laboratory conditions. We then analyzed the potential role of arsenate as an inducer of the expression of this BGC, either alone or in combination with phosphate deprivation. Indeed, we found that the analyzed genes were induced when S. lividans 66 was grown in the presence of 500 µM of arsenic and 3 µM of phosphate (Figure 4B).

In parallel, we used PCR-targeted gene replacement to produce mutants of the SLI1096 and SCO6819 genes, and analyzed the phenotypes of the mutant and wild type strains on a combined arsenate/phosphate gradient, i.e. low phosphate and high arsenate, and vice versa. After this, we cultivated the wild type and mutant strains in liquid cultures, with and without arsenic, during 14 days to obtain enough biomass for chemical analysis. Organic extracts from the pellets of these cultures were analyzed using HPLC coupled with an ICP-MS calibrated to detect arsenic-containing molecular species. Simultaneously, a high-resolution mass spectrometer determined the
mass over charge of the ions detected by the ICP. This set up allows for high-resolution detection of arseno-organic metabolites (54). Using this approach, we detected the presence of arseno-organic metabolites in the organic extracts from the pellets of both wild-type *S. coelicolor* and *S. lividans*, with m/z of 331.1248, 333.1041, and 351.1147 (*Figure 4C* and *Figure S6*). These metabolites could not be detected in either identical extracts from wild type strains grown in the absence of arsenate or in the mutant strains deficient for the SLI1096/SCO6819 genes. Thus, it is tempting to speculate that the product of this pathway may be a relatively polar arsenolipid (*Figure S6*). The actual structures of these products are still subject to further investigation and will be discussed in detail in a future publication.

**EvoMining and its future impact into NP genome mining**

On one hand, confirmation of a link between SLI1096/SCO6819 and the synthesis of an arseno-organic metabolite provides an example on how genome-mining efforts, based in novel enzyme sequences, can be advanced. For instance, co-occurrence of divergent SLI1096 orthologs, now called arsenoenolpyruvate synthases (AEPS); arsenopyruvate mutase (APM) and arsonopyruvate decarboxylase (APD), can be used as beacons to mine publically available bacterial genomes. Indeed, thirteen more BGCs with the potential to synthesize arseno-organic metabolites, all of them encoded in genomes of myceliated *Actinobacteria*, were identified after sequence similarity searches using the non-redundant GenBank database. The divergence and potential chemical diversity within these arseno-related BGCs was characterized after a phylogenetic analysis, using as matrix all conserved genes of these BGCs (*Figure 5*). This analysis suggests three possible sub-classes with distinctive features, PKS-related, PKS-independent and PKS/NRPS hybrid that warrant further investigation.
On the other hand, once an EvoMining hit is validated as an enzyme with an unprecedented function in the context of a hidden BGC, i.e. an EvoMining prediction, this could lead to identification of novel classes of conserved BGCs. To illustrate this, which relates to the 27% of the EvoMining predictions discussed during analysis of the performance of this approach, we focused in the AroA EvoMining tree. The green branches within the NP-related clade of this tree were manually curated in search for a conserved BGC (Figure 1B). One particular case was found to appear frequently, and thus its genes were annotated in detail. For this purpose, fifteen genes upstream and downstream the EvoMining AroA hit were extracted as before, and annotated on the basis of the locus from *S. griseolus* NRRL B-2925, as this organism provides a condensed version of this locus (Table S7). Indeed, the locus has some of the expected features for an NP BGC, including: (i) gene organization suggesting an assembly of operons, most of them (84%) transcribed in the same direction; (ii) genes encoding for enzymes, regulators and potential resistance mechanisms; and (iii) enzymes that have been found in other known NP BGCs. The latter observation, which actually includes seven genes out of thirty-one, present in an equal number of NP BGCs, actually confirms the NP nature of this locus. The reason of why EvoMining did not lead to these homologs as expanded and recruited enzymes has to do with the fact that none of these enzyme families are included within the limited space explored by our PSCP database. Moreover, this BGC was found to be conserved in at least sixty-three *Streptomyces* genomes, and in the genome of *Microtetrastora glauca* NRRL B-3735, included in the non-redundant GenBank database (Table S8).

Thus, we conclude that EvoMining has great potential to ease natural product and drug discovery by means of accelerating the conceptual genome-mining loop that goes from novel enzymatic conversions, their sequences, and propagation after homology searches.
Methods

Bioinformatics methods

*Seed NP database*: NRPS and PKS BGCs were obtained from the DoBISCUIT and ClusterMine 360 databases (10, 11). BGCs for other NP classes were collected from available literature (Table S1). The database included amino acid fasta sequences from GenBank, DoBISCUIT and ClusterMine360. Annotated GenBank formatted files were downloaded from the GenBank database to assemble a database that included 226 BGCs. *Genome database*: Complete and draft genomes of 230 members of the *Actinobacteria* family (Table S1) were retrieved from the GenBank either as single contigs or as groups of contigs in GenBank format, amino acid and DNA sequences were extracted from these files using in-house made scripts. *Precursor supply central pathway (PSCP) database*: the amino acid sequences from the proteins involved in central metabolism were obtained from a database that we assembled for a previous enzyme expansion assessment, published elsewhere (28). The final database for this work included a total of 339 queries for nine pathways, including amino acid biosynthesis, glycolysis, pentose phosphate pathway and tricarboxylic acids cycle (Table S2).

*EvoMining pipeline*: The PSCPs database was used as query to retrieve PSCP enzyme families from the genome database using BlastP (55), with an e-value cutoff of 0.0001 and a score cutoff of 100. At least three query sequences, representing each of the GSMRs used as sources of these sequences (28), were used for Blast searches. The average number of homologs of each enzyme family per genome and the standard deviation were calculated to establish a cutoff to identify and highlight significant expansion events (Table S4). An enzyme family expansion was scored if the number of homologs in at least one genome was higher than the average number of homologs plus
a standard deviation unit. Enzyme families with expansions were used for the next step of the analysis. To identify enzyme recruitments, the amino acid sequences of the seed NP database were used as queries for BlastP searches against expanded enzyme families identified in the previous step using an e-value cutoff of 0.0001 and a bit score cutoff of 100. These parameters were consistent with the approach used by EvoMining, as confirmed heuristically.

The homologs found in known BGCs were added as seeds to the sequences from the expanded enzyme families with recruitments for future clade identification and labeling. These sets of sequences were aligned using Muscle version 3.8.31 (56). The alignments were inspected and curated manually using JalView (57). The curated alignments were used for phylogenetic reconstructions, which were estimated using MrBayes (58) with the following parameters: aamodelpr=mixed, samplefreq=100, burninfrac=0.25 in four chains and for 1000000 generations. The bidirectional best hits with the sequences in the PSCP database were identified and tagged using in-house scripts to distinguish PSCP orthologs from other homologs that result from expansion events. The gene identifiers (GIs) of the EvoMining hits were used as queries to retrieve their genome context as DNA regions of approximately 80 Kbs including the EvoMining hit coding genes. These contigs were retrieved from the genomes in GenBank format using an in-house script. These contigs were annotated using antiSMASH (29) through its web interface. The whole process was executed semi-automatically using in-house scripts written in Perl.

**Gene knockout methods**

*S. coelicolor* (SCO6819) and *S. lividans* 66 (SLI1096) knock-out mutants were constructed using in-frame PCR-targeted gene replacement of their coding sequences with an apramycin resistance cassette (*acc(3)IV*) (59). The plasmid pIJ773 was used as template to obtain a mutagenic cassette
containing the apramycin resistance marker by PCR amplification with the primers reported in Table S9. The mutagenic cassettes were used to disrupt the coding sequences of the genes of interest from the cosmid clone 1A2 that spans from SCO6971 to SCO6824 (60). Given the high sequence identity between the regions covered by cosmid 1A2 with the orthologous region in S. lividans, this cosmid clone was also used for disruption of SLI1096. The gene disruptions were performed using the Redirect system reported elsewhere (59). Double cross-over ex-conjugants were selected using apramycin resistance and kanamycin sensitivity as phenotypic markers. The genotype of the clones was confirmed by PCR. The strains and plasmids of the Redirect system were obtained from the John Innes Centre (Norwich, UK).

The S. roseus leupA mutant was constructed following an insertional mutagenesis strategy. For this purpose, a fragment of 640 bp was amplified by PCR and cloned in the vector pCR2.1-TOPO (ampicillin/kanamycin resistance) using a TA cloning kit from Invitrogen (Carlsbad, USA), to produce the suicide plasmid pLEUPA that cannot be replicated in S. roseus. This plasmid was introduced into S. roseus via protoplasts, generated following standard protocols. The transformants were selected using kanamycin (50µ/mL) and the genotype of the insertional mutants was confirmed by PCR.

**Transcriptional analysis**

The S. lividans 66 wild type strain was grown on 0 and 3; 0 and 300; 500 and 3; 500 and 300 µM of Na3AsO4 and KH2PO4 respectively in solid modified R5 media for eight days. The complete culture conditions used in this work are further detailed in a following section. Mycelium collected from plates was used for RNA extraction with a NucleoSpin RNA II kit (Macherey-Nagel). The RNA samples were used as template for RT-PCR using the one step RT-PCR kit
(Qiagen) (2ng RNA template for each 40 µl reaction). The housekeeping sigma factor *hrdB* (SLI6088) was used as a control.

**S. roseus genome sequencing and library construction**

*S. roseus* ATCC31245 was obtained from the ATCC collection, and its genomic DNA was extracted using common protocols (43) and sequenced at the genomic sequencing facilities of Langebio, Cinvestav-IPN (Irapuato, Mexico), using an Illumina MiSeq platform in paired-end format with read lengths of 250 bases and insert length of 800 bases. In total, 721 Mbp of sequence was obtained. The raw reads were filtered using Trimmomatic (61) and assembled with velvet (62), obtaining a 7.8 Mb assembly in 165 contigs with a coverage of 95 X and a GC content of 72 %. This assembly was annotated using RAST (63) antiSMASH (29) and EvoMining. A genomic library of *S. roseus* ATCC31245 was further obtained for cloning into the pESAC13A vector with an average insert length of 70 Kbps (Bio S&T, Montreal, Canada). pESCA13A is a derivative from pPAC-S1 (64), which has an apramycin resistance as selection marker. This library was screened for the *leup* locus by PCR, leading two clones named 9_18N and 8_10B, containing the desired region. As described further, these constructs were used for heterologous expression in *E. coli*.

**LC-MS metabolite profile analysis**

The SLI1096 and SCO6818 minus mutants were grown on modified R5 medium (K₂SO₄ 0.25 gr; MgCl₂-6H₂O 10.12 gr; glucose 10 gr; casamino acids 0.1 gr; TES buffer 5.73 gr; trace element solution (43) 2 ml; agar 20gr) supplemented with a gradient of KH₂PO₄ and Na₃AsO₄
ranging from 3 to 300 µM and 0 to 500 µM, respectively. Induction of the arseno-organic BGC in both strains was detected in the condition where phosphate is limited and arsenic is available. Therefore, modified R5 liquid media supplemented with 3µM KH₂PO₄ and 500 µM Na₃AsO₄ was used for production of arseno-organic metabolites, and the cultures were incubated for 14 days in shaken flasks with metal springs for mycelium dispersion at 30 C. The mycelium was obtained by filtration, and the filtered mycelium was washed thoroughly with deionized water and freeze-dried. The samples were extracted overnight twice with MeOH/DCM (1:2). The extracts were combined and evaporated to dryness, and the dry residues were re-dissolved in 1 mL of MeOH (HPLC-Grade) and injected to the HPLC. The detection of organic arsenic species was achieved by online-splitting of the HPLC-eluent with 75% going to ESI-Orbitrap MS (Thermo Orbitrap Discovery) for accurate mass analysis and 25% to ICP-QQQ-MS (Agilent 8800) for the detection of arsenic. For HPLC, an Agilent Eclipse XDB-C18 reversed phase column was used with a H₂O /MeOH gradient (0-20 min: 0-100% MeOH; 20-45 min: 100% MeOH; 45-50 min: 100% H₂O). The ICP was set to oxygen mode and the transition ⁷⁵As⁺ -> (⁷⁵As⁶⁺O)⁺ (Q1: m/z = 75, Q2: m/z = 91) was observed. The correction for carbon enhancement from the gradient was achieved using a mathematical approach as described previously (54). The ESI-Orbitrap-MS was set to positive ion mode in a scan range from 250-1100 amu. Also, MS²-spectra for the major occurring ions were generated.

For native leupeptin production wild type *S. roseus* and *LeupA*, mutants were grown in leupeptin production media (65) containing: Glucose 3gr; NH₄NO₃ 0.5gr; MgSO₄ (7H₂O) 0.5gr; KCl 0.05 gr; L-leucine 0.75 gr; L-arginine 0.75 gr; glycine 0.75 gr; casaminoacids 0.1 gr; yeast extract 0.4 gr per liter. These cultures were set up in shaken flasks with metal springs for 48 hours at 30 C. For heterologous production of leupeptins, *E. coli* DH10B transformants carrying the
9_18N and 8_10B PAC clones were grown in Luria-Bertani media (LB) in shaken flasks with 50 µg per mL of apramycin at 37 C for 48 hours. The cultures were centrifuged and the supernatants freeze-dried to obtain 10X concentrates. The crude extracts were analyzed using a C18-218TP vydac column (Grace Healthcare; Columbia, USA) or Restek C18 column (Restek Chromatography; Bellefonte, US), with a 0-100% gradient of [trifluoroacetic acid 0.01% in water]-acetonitrile, and detected by diode array (DAD) at λ=210 nm. Leupeptin authentic standard (L2884, Sigma-Aldrich, St Louis, USA) was used as reference and the peaks with equivalent retention times from the extracts were collected for MS analysis performed on an ion trap LTQ-VELOS equipment in positive mode (Thermo scientific, Waltham, USA) at the MS Unit of Unidad Irapuato Cinvestav-IPN (Irapuato, Mexico).
Acknowledgements

We are indebted with Angélica Cibrián-Jaramillo, Marnix Medema, Paul Straight and Sean Rovito, for useful discussions and critical reading of the manuscript, as well as with Alicia Chagolla and Yolanda Rodriguez of the MS Unit of Unidad Irapuato, Cinvestav, for analytical services. This work was funded by Conacyt Mexico (grants No. 179290 and 177568) and FINNOVA Mexico (grant No. 214716) to FBG. PCM was funded by Conacyt scholarship (No. 28830) and a Cinvestav postdoctoral fellowship. JF and JFK acknowledge funding from the College of Physical Sciences, University of Aberdeen, UK.
References

1. Schreiber S (2005) Small molecules: the missing link in the central dogma. Nature Chemical Biology 1:64–66.

2. Bachmann BO, Van Lanen SG, Baltz RH (2014) Microbial genome mining for accelerated natural products discovery: is a renaissance in the making? J Ind Microbiol Biotechnol 41:175–84.

3. Demain AL (2014) Importance of microbial natural products and the need to revitalize their discovery. J Ind Microbiol Biotechnol 41:185–201.

4. Antimicrobial resistance: global report on surveillance 2014 (World Health Organization-UN). ISBN: 9789241564748.

5. Harvey A, Edrada-Ebel R, Quinn R (2015) The re-emergence of natural products for drug discovery in the genomics era. Nature Reviews Drug Discovery 14:111–129.

6. Bachmann BO, McAlpine JB, Zazopoulos E (2006) Farnesyl dibenzodiazepinone, and processes for its production. US Patent CA2466340 A

7. McAlpine J et al. (2008) Biosynthesis of diazepinomicin/ECO-4601, a Micromonospora secondary metabolite with a novel ring system. Journal of natural products 71:1585–90.

8. Gourdeau H et al. (2007) Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand. Cancer Chemotherapy and Pharmacology 61:911921.

9. Jensen PR, Chavarria KL, Fenical W, Moore BS, Ziemert N (2014) Challenges and triumphs to genomics-based natural product discovery. J Ind Microbiol Biotechnol 41:203–9.

10. Conway K, Boddy C (2013) ClusterMine360: a database of microbial PKS/NRPS biosynthesis. Nucleic Acids Research 41:D402–D407.

11. Ichikawa N et al. (2013) DoBISCUIT: a database of secondary metabolite biosynthetic gene clusters. Nucleic acids research 41:D408–14.

12. Barona-Gómez F, Wong U, Giannakopoulos A, Derrick P, Challis G (2004) Identification of a Cluster of Genes that Directs Desferrioxamine Biosynthesis in StreptomycescoelicolorM145. Journal of the American Chemical Society 126:1628216283.

13. Lautru S, Deeth R, Bailey L, Challis G (2005) Discovery of a new peptide natural product by Streptomyces coelicolor genome mining. Nature Chemical Biology 1:265–269.
14. Udwary D et al. (2007) Genome sequencing reveals complex secondary metabolome in the marine actinomycete Salinispora tropica. *Proceedings of the National Academy of Sciences* 104:10376–10381.

15. Challis G (2008) Mining microbial genomes for new natural products and biosynthetic pathways. *Microbiology (Reading, England)* 154:1555–69.

16. Metcalf W, Donk W (2009) Biosynthesis of phosphonic and phosphinic acid natural products. *Biochemistry* 78:65–94.

17. Yu X et al. (2013) Diversity and abundance of phosphonate biosynthetic genes in nature. *Proceedings of the National Academy of Sciences* 110:20759–20764.

18. Ju K-S, Doroghazi J, Metcalf W (2013) Genomics-enabled discovery of phosphonate natural products and their biosynthetic pathways. *Journal of Industrial Microbiology & Biotechnology*.

19. Arnison P et al. (2012) Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. *Natural Product Reports* 30:108–160.

20. Thaker M et al. (2013) Identifying producers of antibacterial compounds by screening for antibiotic resistance. *Nature Biotechnology* 31:922–927.

21. Gerlt JA, Babbitt PC (2001) Divergent evolution of enzymatic function: mechanistically diverse superfamilies and functionally distinct superfamilies. *Annual review of biochemistry* 70:209–46.

22. Caetano-Anollés G et al. (2009) The origin and evolution of modern metabolism. *Int J Biochem Cell Biol* 41:285–97.

23. Tahlan K, Park HU, Wong A, Beatty PH, Jensen SE (2004) Two sets of paralogous genes encode the enzymes involved in the early stages of clavulanic acid and clavam metabolite biosynthesis in Streptomyces clavuligerus. *Antimicrob Agents Chemother* 48:930–9.

24. Verdel-Aranda K, López-Cortina ST, Hodgson DA, Barona-Gómez F (2015) Molecular annotation of ketol-acid reductoisomerases from Streptomyces reveals a novel amino acid biosynthesis interlock mediated by enzyme promiscuity. *Microbial biotechnology* 8:239–52.

25. Vining LC (1992) Secondary metabolism, inventive evolution and biochemical diversity - a review. *Gene* 115:135–40.

26. Firn R, Jones C (2009) A Darwinian view of metabolism: molecular properties determine fitness. *Journal of Experimental Botany* 60:719–726.
27. Medema MH, Cimermancic P, Sali A, Takano E, Fischbach MA (2015) A systematic computational analysis of biosynthetic gene cluster evolution: lessons for engineering biosynthesis. *PLoS computational biology* 10:e1004016.

28. Barona-Gómez F, Cruz-Morales P, Noda-García L (2011) What can genome-scale metabolic network reconstructions do for prokaryotic systematics? *Antonie van Leeuwenhoek* 101:35–43.

29. Blin K et al. (2013) antiSMASH 2.0--a versatile platform for genome mining of secondary metabolite producers. *Nucleic acids research* 41:W204–12.

30. Cimermancic P et al. (2014) Insights into Secondary Metabolism from a Global Analysis of Prokaryotic Biosynthetic Gene Clusters. *Cell* 158:412-21.

31. Blodgett JA et al. (2007) Unusual transformations in the biosynthesis of the antibiotic phosphinothricin tripeptide. *Nat Chem Biol* 3:480–5.

32. Aoyagi T, Takeuchi T, Matsuzaki A, Kawamura K, Kondo S (1969) Leupeptins, new protease inhibitors from Actinomycetes. *The Journal of antibiotics* 22:283–6.

33. Suzukake K, Fujiyama T, Hayashi H, Hori M (1979) Biosynthesis of leupeptin. II. Purification and properties of leupeptin acid synthetase. *The Journal of antibiotics* 32:523-30

34. Hori M, Hemmi H, Suzukake K, Hayashi H (1978) Biosynthesis of leupeptin. *The Journal of antibiotics* 31:95-8

35. Suzukake K, Hori M, Tamemasa O, Umezawa H (1981) Purification and properties of an enzyme reducing leupeptin acid to leupeptin. *Biochim Biophys Acta.* 661:175-81.

36. Suzukake K, Hayashi H, Hori M (1980) Biosynthesis of leupeptin. III. Isolation and properties of an enzyme synthesizing acetyl-L-leucine. *The Journal of antibiotics* 33:857-62

37. Chen Y, McClure R, Zheng Y, Thomson R, Kelleher N (2013) Proteomics guided discovery of flavopeptins: anti-proliferative aldehydes synthesized by a reductase domain-containing non-ribosomal peptide synthetase. *Journal of the American Chemical Society* 135:10449–56.

38. Rausch C, Hoof I, Weber T, Wohlleben W, Huson DH (2007) Phylogenetic analysis of condensation domains in NRPS sheds light on their functional evolution. *BMC evolutionary biology* 7:78.

39. Sampaleanu LM, Vallée F, Thompson GD, Howell PL (2002) Three-dimensional structure of the argininosuccinate lyase frequently complementing allele Q286R. *Biochemistry* 40:15570–80.

40. Kaysser L et al. (2011) Identification of a napsamycin biosynthesis gene cluster by genome mining. *Chembiochem* 12:477–87.
41. Zhang W, Ostash B, Walsh CT (2010) Identification of the biosynthetic gene cluster for the pacidamycin group of peptidyl nucleoside antibiotics. *Proceedings of the National Academy of Sciences of the United States of America* 107:16828–33.

42. Challis GL (2014) Exploitation of the Streptomyces coelicolor A3(2) genome sequence for discovery of new natural products and biosynthetic pathways. *J Ind Microbiol Biotechnol* 41:219–32.

43. Kieser T, Bibb MJ, Buttner MJ, Chater KF, Hopwood DA (2000) *Practical Streptomyces genetics* (The John Innes Foundation, Norwich UK).

44. Zhang F, Berti PJ (2006) Phosphate analogues as probes of the catalytic mechanisms of MurA and AroA, two carboxyvinyl transferases. *Biochemistry* 45:6027–37.

45. Rui Z et al. (2010) Biochemical and genetic insights into asukamycin biosynthesis. *The Journal of biological chemistry* 285:24915–24.

46. Seeger K et al. (2011) The biosynthetic genes for prenylated phenazines are located at two different chromosomal loci of Streptomyces cinnamonensis DSM 1042. *Microbial biotechnology* 4:252–62.

47. Cruz-Morales P et al. (2013) The Genome Sequence of Streptomyces lividans 66 Reveals a Novel tRNA-Dependent Peptide Biosynthetic System within a Metal-Related Genomic Island. *Genome Biology and Evolution* 5:1165–1175.

48. Nett M, Ikeda H, Moore BS (2009) Genomic basis for natural product biosynthetic diversity in the actinomycetes. *Nat Prod Rep* 26:1362–84.

49. Bentley SD et al. (2002) Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2). *Nature* 417:141–7.

50. Wang L et al. (2006) arsRBOCT arsenic resistance system encoded by linear plasmid pHZ227 in Streptomyces sp. strain FR-008. *Applied and environmental microbiology* 72:3738–42.

51. Elias M et al. (2012) The molecular basis of phosphate discrimination in arsenate-rich environments. *Nature* 491:134–137.

52. Tawfik D, Viola R (2011) Arsenate replacing phosphate: alternative life chemistries and ion promiscuity. *Biochemistry* 50:1128–34.

53. Chawla S, Mutenda EK, Dixon HB, Freeman S, Smith AW (1995) Synthesis of 3-arsonopyruvate and its interaction with phosphoenolpyruvate mutase. *The Biochemical journal* 308 (Pt 3):931–5.
54. Amayo KO, Raab A, Krupp EM, Gunnlaugsdottir H, Feldmann J (2013) Novel identification of arsenolipids using chemical derivatizations in conjunction with RP-HPLC-ICPMS/ESMS. *Analytical chemistry* 85:9321–7.

55. Camacho C et al. (2009) BLAST+: architecture and applications. *BMC Bioinformatics* 10:421.

56. Edgar RC (2004) MUSCLE: multiple sequence alignment with high accuracy and high throughput. *Nucleic acids research* 32:1792–7.

57. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ (2009) Jalview Version 2--a multiple sequence alignment editor and analysis workbench. *Bioinformatics (Oxford, England)* 25:1189–91.

58. Ronquist F et al. (2012) MrBayes 3.2: efficient Bayesian phylogenetic inference and model choice across a large model space. *Systematic biology* 61:539–42.

59. Gust B, Challis G, Fowler K, Kieser T, Chater K (2003) PCR-targeted Streptomyces gene replacement identifies a protein domain needed for biosynthesis of the sesquiterpene soil odor geosmin. *Proceedings of the National Academy of Sciences* 100:1541–1546.

60. Redenbach M et al. (1996) A set of ordered cosmids and a detailed genetic and physical map for the 8 Mb Streptomyces coelicolor A3(2) chromosome. *Molecular microbiology* 21:77–96.

61. Bolger AM, Lohse M, Usadel B (2014) Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics (Oxford, England)* 30:2114–20.

62. Zerbino DR, Birney E (2008) Velvet: algorithms for de novo short read assembly using de Bruijn graphs. *Genome research* 18:821–9.

63. Aziz RK et al. (2008) The RAST Server: rapid annotations using subsystems technology. *BMC genomics* 9:75.

64. Sosio M et al. (2000) Artificial chromosomes for antibiotic-producing actinomycetes. *Nature biotechnology* 18:343–5.

65. Takagi K, Yamamoto Y, Yamazaki T, Yamaguchi H, Umezawa H (1978) Process for producing L-leupeptins. *US patent 4066507 A.*
Figure legends

**Figure 1. EvoMining pipeline for the recapitulation of the evolution of NP biosynthesis.** A. Bioinformatic workflow: The three input databases, as discussed in the text, are shown in green. Internal databases are shown in yellow, whereas grey boxes depict processes. B. An example of a typical EvoMining phylogenetic tree (**Tree S4**) using the case of 3-carboxyvinyl-phosphoshikimate synthase family. Red branches include homologs related to central metabolism and their topology resembles that of a species guide tree (**Tree S1**), while blue branches have been recruited into known BGCs. Cyan branches are EvoMining hits found within regions recognised as NP-related also by antiSMASH or ClusterFinder. Green branches are not classifiable by other methods and thus represent EvoMining predictions that may form part of BGCs for novel classes of NPs (see **Figure 2A** for further details).

**Figure 2. Analysis of EvoMining Hits.** A. Pie chart of the whole set of EvoMining hits as annotated using antiSMASH and ClusterFinder. B. Diversity of BGCs per recruited enzyme family. Top panel, the number of hits and BGC classes per family are compared; as the number of hits increases, more BGC classes are found. Bottom panel, a diversity plot for each enzyme family, showing the proportion and number of BGC classes, defines by AntiSMASH. The label “Detected by ClusterFinder” means EvoMining hits that are also found by this algorithm, whereas the label “EvoMining predictions” includes all hits that could not be detected by antiSMASH or Cluster Finder.
Figure 3. Discovery of the BGC for leupeptin. A. Left panel, phylogenetic reconstruction of the actinobacterial argininosuccinate lyase enzyme family (Tree S3). Homologs related to central metabolism are shown in red branches. A clade including recruited homologs is shown in cyan. The LeupB homolog from S. roseus, a leupeptin producer, together with the known recruitments for pacidamycin and napsamycin (blue branches), are indicated. B. Genome context of leupB, including leupA (novel NRPS), leupC (annotated as threonine kinase) and leupD (annotated as cysteine synthase). The enzyme functions in the context of leupeptin biosynthesis remain to be characterized. C. Biosynthetic proposal for leupeptin, based in the EvoMining prediction and earlier biochemical analyses. LeupA is proposed to produce Acyl-Leu-Leu, which is used by LeupB, together with arginine, for the synthesis of leupeptidic acid. A reductase activity, that remains to be identified, is required for formation of the characteristic aldehyde group.

Figure 4. Discovery of a BGC for arseno-organic NPs in S. coelicolor and lividans. A. BGC for arseno-organic biosynthesis in S. lividans 66 and S. coelicolor are indicated. The proposed biosynthetic logic for early intermediates in the biosynthesis of arseno-organic metabolites is shown. B. Transcriptional analysis of selected genes within the arseno-organic BGC, showing that the expression of the genes is repressed under standard conditions, but induced upon the presence of arsenate. C. HPLC-Orbitrap/QQQ-MS trace of organic extracts from mycelium of wild type and the SLI_1096 mutant showing the detection of arsenic-containing species. Three m/z signals were detected within the two peaks found in the trace from the wild type strain grown on the presence of arsenate. These m/z signals are absent from the wild type strain grown without arsenate, and from the mutant strain grown on phosphate limitation and the presence of arsenate.
Identical results were obtained for *S. coelicolor* and the SCO6819 mutant when tested in identical conditions.

**Figure 5. Novel BGCs for arseno-organic metabolites found in Actinobacteria.** The BGCs were found by mining for the co-occurrence of arsenoenol pyruvate synthase (AEPS), arsenopyruvate mutase (APM), arsenoenolpyruvate decarboxylase (APD), in available bacterial genomes from the GenBank, as of November 2014. Related BGCs were only found in actinomycetes. The phylogeny was constructed with a concatenated matrix of conserved enzymes among the BGCs that included AEPS, APM, APD (purple arrows), plus CTP synthase and anaerobic dehydrogenase (shown as blue arrows together with other enzymes). Variations in the functional content of the BGCs are accounted by PKSs (red arrows), hybrid PKS-NRPS (yellow genes), arsenic regulation and metabolism proteins (brown arrows), and other regulators and transporters (green arrows). Three main classes or arseno-organic BGCs could be expected from this analysis: PKS-independent, PKS-NPRS-dependent and PKS-dependent biosynthetic systems. Dotted lines indicate sequence gaps, and an asterisk marks the sequence from *Nocardiopsis lucentensis*, which is assumed that have a missing PKS gene in one of the sequence gaps.
Orthologs from central metabolism

Expansions recruited into natural product BGCs

Streptomyces roseus

Napsamycin
Pacidamycin

---

A

B

| AT | A₁ | T | C | A₂ | TE |
|----|----|---|---|----|----|
|    |    |   |   |    |    |
| leupA | leupB | leupC | leupD |

- NRPS
- Threonine kinase
- Argininosuccinate lyase
- Cysteine synthase

---

C

AT A₉ Leu C A₉ Leup B₉ TE

Leupeptidic acid

Leupeptin

LeupA

LeupB

LeupB

Leup?
A

Polyketide synthase  As-C bond biosynthesis  As regulation and metabolism  Transport  Other enzymes

B

|  |  |  |  |
|---|---|---|---|
| hrdB | SLI1088 | SLI1096 | SLI1099 | SLI1103 |
| 3 μM KH₂PO₄ / 0 μM Na₂AsO₄ |  |  |  |  |
| 3 μM KH₂PO₄ / 500 μM Na₂AsO₄ |  |  |  |  |

C

Retention time [min]

S. lividans wild-type with As
m/z+H = 331.1041 (As-C₃H₅O₄)

S. lividans SLI1096::acc(3)/w with As
m/z+H = 351.1147 (As-C₃H₇O₄)

S. lividans wild-type without As
m/z+H = 331.12489 (As-C₃H₅O₄)
